BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/10/2018 9:12:36 AM | Browse: 586 | Download: 911
Publication Name World Journal of Transplantation
Manuscript ID 39945
Country/Territory Japan
Received
2018-05-21 02:12
Peer-Review Started
2018-05-21 08:08
To Make the First Decision
2018-06-06 07:36
Return for Revision
2018-06-08 01:24
Revised
2018-06-23 07:40
Second Decision
2018-06-26 12:32
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-06-28 04:04
Articles in Press
2018-06-28 04:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-09-06 04:09
Publish the Manuscript Online
2018-09-07 06:15
ISSN 2220-3230 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Minireviews
Article Title Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
Manuscript Source Invited Manuscript
All Author List Junji Uchida, Tomoaki Iwai and Tatsuya Nakatani
Funding Agency and Grant Number
Corresponding Author Junji Uchida, MD, PhD, Associate Professor, Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3, Abeno-ku, Asahi-machi, Osaka 545-8585, Japan. m9492120@msic.med.osaka-cu.ac.jp
Key Words Kidney transplantation; Everolimus; mTOR inhibitor; Late conversion; Calcineurine inhibitor
Core Tip Current immunosuppressive protocols consisting of calcineurin inhibitors (CNIs) and mycophenolate mo­fetil have improved short-term graft survival. However, improvements in long-term graft survival are restricted by nephrotoxicity associated with CNI. Everolimus is an exceedingly useful immunosuppressant for kidney transplant recipients when administered in combination with low-dose CNIs or with elimination of CNIs. Here, we summarize the current knowledge about the introduction of everolimus with CNI elimination or minimization in kidney transplant recipients at late posttransplant stage.
Publish Date 2018-09-07 06:15
Citation Uchida J, Iwai T, Nakatani T. Introduction of everolimus in kidney transplant recipients at a late posttransplant stage. World J Transplant 2018; 8(5): 150-155
URL http://www.wjgnet.com/2220-3230/full/v8/i5/150.htm
DOI http://dx.doi.org/10.5500/wjt.v8.i5.150
Full Article (PDF) WJT-8-150.pdf
Manuscript File 39945-Review.docx
Answering Reviewers 39945-Answering reviewers.pdf
Audio Core Tip 39945-Audio core tip.MP3
Conflict-of-Interest Disclosure Form 39945-Conflict-of-interest statement.pdf
Copyright License Agreement 39945-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 39945-Language certificate.pdf
Peer-review Report 39945-Peer-review(s).pdf
Scientific Misconduct Check 39945-Scientific misconduct check.pdf
Scientific Editor Work List 39945-Scientific editor work list.pdf